Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Multiple Myeloma, Plasmacytoma

In brief

The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.

Key facts

Study ID

NCT06429150

Run by

Shenzhen Geno-Immune Medical Institute

People needed

20

Starts

2024-05-11

Expected to finish

2027-12-31

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects with multiple myeloma or plasmacytoma
• Strictly complete remission (sCR) is a treatment goal
• Expected survival > 12 weeks
• After prior auto-SCT is eligible regardless of other prior therapies
• Adequate venous access for apheresis, and no other contraindications for leukapheresis
• Voluntary informed consent is given and commitment to continued follow-up

You may not qualify if…

• Pregnant or lactating women
• Uncontrolled active infection
• Active HIV, hepatitis B or hepatitis C infection
• Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
• Any medical conditions that may preclude participation

Where it is running

• Shenzhen Geno-immune Medical Institute — Shenzhen, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.